F2G appoints Camilla Soenderby to Board of Directors

Biopharma leader brings extensive international leadership experience in portfolio strategy and commercialisation

MANCHESTER, UK, PRINCETON, NJ & VIENNA, AUSTRIA –15 September 2021 – F2G Ltd, a clinical-stage biopharmaceutical company focused on rare life-threatening fungal diseases with a high unmet medical need, today announces the appointment of Camilla Soenderby as a Non-Executive Director to its Board of Directors with immediate effect.

Camilla Soenderby is a seasoned biopharma executive with 20 years of international leadership experience from senior strategic and operational roles spanning C-level, global, regional, and country level for leading biopharma companies in the EU, US and Asia. She has a proven track record of developing and growing businesses and has successfully led worldwide cross functional teams to drive portfolio strategy and commercialisation of therapies to treat rare diseases, oncology and specialty conditions.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...